Factors Affecting Recovery Time after Sedation for Upper Gastrointestinal Endoscopy

Hwa-jung Jin¹, Min-Ho Shin², and Eun Myung³,*

¹Department of Public Health, Graduate School, Chonnam National University Medical School, ²Department of Preventive Medicine, Chonnam National University Medical School, ³Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea

The purpose of this study was to investigate factors affecting recovery time after sedation for upper gastrointestinal endoscopy. The study population included 1310 patients in the national gastric cancer screening program who received sedation for upper gastrointestinal endoscopy from April 15, 2015 to December 31, 2018. Multivariate regression analysis was performed to identify factors related to recovery time. The mean recovery time after examination was 51.2 minutes (SD=13.3). Patients with a history of hypertension had a recovery time 2.59 minutes shorter than that of patients without hypertension (p=0.006, Bonferroni-corrected p=0.108). Patients with a history of stroke had a recovery time 9.41 minutes longer than that of patients without stroke (p=0.007, Bonferroni-corrected p=0.124). Patients who received 3 mg midazolam had a recovery time 2.99 minutes longer than that of patients received 2 mg (p=0.001, Bonferroni-corrected p=0.010), and patients who received less than 6 cc of propofol had a recovery time 2.90 minutes longer than those that of patients received 7-12 cc of propofol (p<0.001, Bonferroni-corrected p=0.005). These results suggest that receiving high doses of midazolam and having a history of stroke are associated with longer recovery times. Patients meeting these criteria should be managed carefully after sedation for upper gastrointestinal endoscopy.

Key Words: Conscieus Sedation; Endoscopy; Gastrointestinal; Midazolam

INTRODUCTION

Gastrointestinal endoscopy (GIE) is a diagnostic tool used for direct observation of the gastric mucosa. It is a highly sensitive test that is essential to diagnosing gastrointestinal diseases.¹ GIE is increasingly being used because of government support for cancer screening and growing interest in preventive medicine.² Sedation is used for GIE to reduce patient’s anxiety and discomfort while increasing patient satisfaction. Sedation also minimizes the risk of patient injury during GIE and provides ideal working conditions for the endoscopist, thereby increasing patient satisfaction with the procedure.³,5 As a result of these advantages, the frequency with which sedation is used for GIE is gradually increasing worldwide and also in Korea.⁵,6 In the United States, most GIEs are performed under sedation to control pain and reduce anxiety.⁶,⁹ Sedation can be classified into four levels: minimal sedation (anxiolysis), conscious sedation, deep sedation, and general anesthesia.¹⁰ When sedating a patient for endoscopy, the aim is moderate sedation.¹¹,¹² However, the level of patient consciousness may vary by operator and patient because the depth of sedation depends on the quantity of sedatives used and the patient’s response.¹¹,¹³ It is very important to maintain an appropriate level of sedation.¹⁴ If sedation is too light, the patient may make unconscious movements and make the exam difficult for the endoscopist. If sedation is too deep, respiratory distress, hypotension, or other adverse events can occur.¹⁵ Since sedation for GIE reduces the patient’s level of consciousness, a recovery period is required.¹⁶-¹⁸ It is important to prevent these adverse events and provide a safe examination for patients. Also, it is necessary to shorten
the length of stay in the recovery room by reducing the recovery time to increase economic efficiency.

The identification of factors related to recovery time after sedation can help reduce adverse effects, ensure patient safety during GIE and increase economic efficiency.

Some studies have suggested that age, pulmonary function, alcohol intake, and gender are the factors most related to recovery time after sedation. However, most previous studies have focused on evaluating sedative drugs rather than identifying factors related to recovery time. The aim of this study is to investigate the factors affecting recovery time after sedation for GIE in order to manage patients safely and provide adequate assistance during the recovery period.

MATERIALS AND METHODS

1. Study population

In total, 1409 patients were sedated for GIE during gastrointestinal cancer screenings by the National Health Insurance Service at Chonnam National University Bitgoeul Hospital from April 15, 2015 to December 31, 2018. Of them, 1310 were included in the final study analysis; the other 99 patients were excluded for the following reasons: not having a general checkup (66 patients); having incomplete medical records (17 patients); receiving a single drug except midazolam or propofol (10 patients); or using antagonists for changes in condition during sedation or for other reasons (6 patients). This study’s protocol was approved by the Institutional Review Board of Chonnam National University Hospital (IRB No. CNUH-2019-233). The requirement to obtain participant consent was waived because of the retrospective nature of the study.

2. Data collection

Data was collected using electronic medical records. We recorded the following data for each patient: gender, age, body mass index (BMI), smoking status, alcohol intake, physical activity, medical history, liver function, kidney function, and anemia. BMI was defined as weight (kg) divided by height squared (m²), and obesity was defined as a BMI of 25 kg/m² or more. Smoking status, alcohol intake, and physical activity were recorded as binary variables (yes/no). We also recorded history of stroke, heart disease (myocardial infarction, angina pectoris), hypertension, diabetes, and history of sedation. History of hypertension was defined as “yes” if the patient had been diagnosed previously based on health checkup questionnaire. Liver function was considered abnormal when aspartate amino transferase (AST) was higher than 40 U/L or alanine amino transferase (ALT) was higher than 40 U/L. Anemia was defined as a hemoglobin level below 13 g/dL in men and 12 g/dL in women. Kidney function was evaluated using an estimated glomerular filtration rate (eGFR), which was calculated with the Modification of Diet in Renal Disease (MDRD) formula. Patients with a GFR <60 mL/min/1.73 m² for 3 months are defined as having chronic kidney disease (CKD). Examination time was defined as the time from the start of sedation to the end of the examination.

3. Measurement of recovery time after examination

Recovery time was defined as the time from the removal of the endoscopic device at the end of the examination, to the time of the patient’s departure from the recovery room. The criteria for exiting the recovery room were based on the Modified Aldrete Score. This measure assessed recovery from anesthesia using objective information about the patient’s physical condition. The higher the score, the better the recovery. Five items are used to evaluate of recovery: reflex ability, oxygen saturation, breathing, circulation, and consciousness. Patients can be given a maximum of two points per item. Patients included in this study were permitted to leave when they had reached a score of 10 points (the highest possible score). A recovery score of 10 means that fully recovered, and able to move all limbs spontaneously, breathe deeply, maintain a blood pressure within ±20% of their blood pressure before sedation, and maintain oxygen saturation of 92% or greater in atmosphere.

4. Statistical analysis

Multivariate linear regression analysis was performed to evaluate factors related to recovery time after GIE.

### Table 1. General characteristics of study participants according to the gender

|                | Men       | Women     | Total     |
|----------------|-----------|-----------|-----------|
| N              | 468 (35.7)| 842 (64.3)| 1310 (100.0)|
| Age            | 57.3±10.4 | 56.9±10.1 | 57.1±10.2 |
| Obese (BMI>=25kg/m²) | 202 (43.2)| 285 (33.8)| 487 (37.2)|
| Current smoking| 119 (25.4)| 14 (1.7)  | 133 (10.2)|
| Alcohol intake | 245 (52.4)| 136 (16.2)| 381 (29.1)|
| Physical activity| 207 (44.2)| 338 (40.1)| 545 (41.6)|
| History of hypertension | 132 (28.2)| 201 (23.9)| 333 (25.4)|
| History of diabetes mellitus| 82 (17.5)| 90 (10.7)| 172 (13.1)|
| History of stroke | 10 (2.1)| 5 (0.6)| 15 (1.1)|
| History of ischemic heart disease | 24 (5.1)| 35 (4.2)| 59 (4.5)|
| Elevated liver function | 101 (21.6)| 84 (10.0)| 185 (14.1)|
| Anemia | 25 (5.3)| 92 (10.9)| 117 (8.9)|
| Chronic kidney disease | 12 (2.6)| 15 (1.8)| 27 (2.1)|
| History of sedation | 443 (94.7)| 790 (93.8)| 1233 (94.1)|
| Midazolam | | | |
| Low (≤2 mg) | 151 (32.3)| 505 (60.0)| 656 (50.1)|
| High (3 mg) | 317 (67.7)| 337 (40.0)| 654 (49.9)|
| Propofol | | | |
| Low (≤6 cc) | 179 (38.2)| 423 (50.2)| 602 (46.0)|
| Moderate (7-12 cc) | 277 (59.2)| 404 (48.0)| 681 (52.0)|
| High (≥13 cc) | 12 (2.6)| 15 (1.8)| 27 (2.1)|
| Recovery time, minutes | 51.6±13.3| 50.9±13.2| 51.2±13.3|
| Examination time, minutes | 9.0±3.2| 8.4±2.8| 8.6±2.9|

Values are mean (SD) or number (%).

BMI: body mass index. 1AST or ALT >40 U/L. 2Hemoglobin men <13 g/dL, women<12 g/dL. 3MDRD e-GFR <60 mL/min/1.73 m².
Independent variables included age, gender, obesity, smoking, alcohol intake, physical activity, hypertension, diabetes, stroke, ischemic heart disease, liver function, anemia, chronic kidney disease, history of sedation, amount of midazolam and propofol, and examination time.

Patient groups were divided based on the dose of midazolam and propofol: 3 mg vs. ≤ 2 mg (midazolam), ≤ 6 cc vs. 7-12 cc vs. ≥ 13 cc (propofol). In addition, the Bonferroni-corrected p-value was presented to account for multiple comparison in the multivariate linear regression. Statistical analyses were performed using STATA/SE 15.0 (StataCorp, College Station, TX, USA).

RESULTS

1. Patient characteristics

In total, 1310 patients were included in the analyses. Table 1 lists their characteristics by gender. The proportion of women was high, with 842 females (64.3%) versus 468 males (35.7%). The mean age was 57.1 years; (men: 57.3 years; women: 56.9 years). After sedation for GIE, the mean recovery time was 51.2±13.3 minutes (men: 51.6±13.3 minutes; women: 50.9±13.3 minutes) (Fig. 1). Recovery time for patients with a history of hypertension was 2.59 minutes shorter than that of patients without hypertension (p=0.006, Bonferroni-corrected p=0.108) and patients with a history of stroke had a recovery time 9.41 minutes longer than that of patients without a history of stroke (p=0.007, Bonferroni-corrected p=0.124) (Table 2).

2. Sedative dose and recovery time

Recovery time for patients receiving a higher dose of midazolam (3 mg) was 2.99 minutes longer than recovery time for patients receiving a lower dose of midazolam (≤ 2 mg) (p=0.001, Bonferroni-corrected p=0.010). Patients who received less than 6 cc propofol had a recovery time 2.90 minutes longer than that of those who received 7-12 cc propofol (p<0.001, Bonferroni-corrected p=0.005). Patients who received more than 13 cc propofol had a recovery time 1.86 minutes longer than that of those who received 7-12 cc propofol (p=0.477, Bonferroni-corrected p=1.000) (Table 2).

3. Factors related to recovery time

Patient characteristics and sedative dose were investigated and analyzed. Patients with a history of hypertension had a recovery time 2.59 minutes shorter than that of patients without hypertension (p=0.006, Bonferroni-corrected p=0.108). Patients with a history of stroke had a recovery time 9.41 minutes longer than that of patients without a history of stroke (p=0.007, Bonferroni-corrected p=0.124) (Table 2). Patients receiving a higher dose of midazolam (3 mg) had a recovery time 2.99 minutes longer than that of patients receiving a lower dose of midazolam (≤ 2 mg) (p=0.001, Bonferroni-corrected p=0.010). Patients who received less than 6 cc propofol had a recovery time 2.90 minutes longer than that of those who received 7-12 cc propofol (p<0.001, Bonferroni-corrected p=0.005).

This analysis revealed that a history of hypertension and stroke history had a tendency to be related to recovery time. However, there was no statistical significance in multiple comparisons of the multivariate linear regression. Dose of midazolam and propofol are factors related to recovery time.

DISCUSSION

The purpose of this study was to identify factors related to recovery time after sedation for GIE in patients in the national gastric cancer screening by the National Health Insurance Service. Two factors had a tendency to affect recovery time after sedation for GIE: history of hypertension and history of stroke. Dose of sedative also affected recovery time after sedation for GIE with statistical significance. Patients who had a history of hypertension (p=0.006, Bonferroni-corrected p=0.108) had shorter recovery times. Patients who had a history of stroke (p=0.007, Bonferroni-corrected p=0.124) or received high doses of midazolam (3 mg vs. ≤ 2 mg, p=0.001, Bonferroni-corrected p=0.010) had longer recovery times.

A previous study involving 103 patients used a stepwise regression analysis to identify factors affecting recovery time. It found that recovery time was longer for patients with poor pulmonary function, and that alcohol intake was associated with shorter recovery time.20 In an Israeli study of 405 people, age was the only factor affecting recovery time. The authors reported that age accounted for approximately 2% of the variation in recovery time.19 Another study related to prolonged recovery time included 31,442 patients and found that women had longer recovery times.21

In the present study, however, alcohol intake, age, and gender were not related to recovery time after sedation.

Previous studies have not found an association between recovery time and a history of hypertension or stroke.19-21 In our study population, recovery time after sedation for upper GIE was 2.59 minutes shorter in patients with a his-
Factors Affecting Recovery Time after Sedation for GI Endoscopy

**Table 2. Factors affecting recovery time (minutes) after sedation gastroscopy by the multivariate linear regression analysis**

| Factors                                      | Regression coefficient (95% CI) | p-value | Bonferroni-corrected p-value |
|----------------------------------------------|--------------------------------|---------|-------------------------------|
| Age (one year)                               | 0.05 (−0.05-0.14)              | 0.345   | 1.000                         |
| Gender (women vs men)                        | −0.54 (−2.33-1.25)             | 0.557   | 1.000                         |
| Obese (BMI≥25 kg/m² vs BMI<25 kg/m²)         | 1.22 (0.36-2.79)               | 0.130   | 1.000                         |
| Current smoking (yes vs no)                  | −0.37 (−3.00-2.24)             | 0.780   | 1.000                         |
| Alcohol intake (yes vs no)                   | −1.04 (−2.80-0.72)             | 0.247   | 1.000                         |
| Physical activity (yes vs no)                | −0.77 (−2.24-0.70)             | 0.36    | 1.000                         |
| History of hypertension (yes vs no)          | −2.59 (−4.44−0.74)             | 0.006   | 0.108                         |
| History of diabetes mellitus (yes vs no)     | 0.50 (−1.76-2.77)              | 0.662   | 1.000                         |
| History of stroke (yes vs no)                | 9.41 (2.59-16.22)              | 0.007   | 0.124                         |
| History of ischemic heart disease (yes vs no)| 1.85 (−1.66-5.37)             | 0.302   | 1.000                         |
| Elevated liver function¹ (yes vs no)         | −0.13 (−2.25-1.99)             | 0.905   | 1.000                         |
| Anemia² (yes vs no)                          | 0.30 (−2.26-2.86)              | 0.820   | 1.000                         |
| Chronic kidney disease³ (yes vs no)          | −0.06 (−3.12-2.99)             | 0.967   | 1.000                         |
| History of sedation (yes vs no)              | 2.65 (−0.39-5.68)              | 0.087   | 1.000                         |
| Midazolam (3 mg vs ≤2 mg)                    | 2.99 (1.30-4.68)               | 0.001   | 0.010                         |
| Propofol                                      |                                |         |                               |
| ≤6 cc vs 7-12 cc                             | 2.90 (1.35-4.45)               | <0.001  | 0.005                         |
| ≥13 cc vs 7-12 cc                            | 1.86 (−3.27-7.00)              | 0.477   | 1.000                         |
| Examination time (one minute)                | −0.186 (−0.431-0.06)           | 0.136   | 1.000                         |

BMI: body mass index.

¹AST or ALT >40 U/L, ²Hemoglobin men<13 g/dL, women<12 g/dL, ³MDRD e-GFR≤60 mL/min/1.73 m².

Recovery time was 51.2 minutes. Recovery time after sedation for GIE is generally considered to be 30 minutes or more, because serious side effects tend to occur within 25 minutes of the last administration of sedative drugs.17,22

Unlike previous studies evaluating sedative drugs, the present study investigated factors related to recovery time after sedation for GIE and identified factors associated with long recovery times. However, the study had some limitations. First, investigation of the relationship between short recovery times and a history of hypertension was limited by our inability to include information on hypertension medication. The biological mechanism of the association between hypertension and recovery time is uncertain, and further studies are needed. Second, previous studies have found a relationship between alcohol intake and short recovery time.28 Our study included patient alcohol intake as a binary variable (yes/no). Patients’ level of alcohol intake was not analyzed because the data was not available. Further studies of the relationship between alcohol intake and recovery time are needed.

Overall, we found that factors related to recovery time related factors after sedation for upper GIE included having a history of stroke or hypertension and receiving a high dose of midazolam. Patients meeting these criteria should be carefully managed. To respond effectively to dangerous situations and avoid complications, factors relevant to recovery time after sedation for GIE should be identified before the procedure is performed. Safe and appropriate patient management is required after endoscopic examination to ensure proper recovery.

194
ACKNOWLEDGEMENTS

This manuscript is a revision of the first author's master thesis from Chonnam National University.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Lee SH, Lee DJ, Kim KM, Park SB, Kim BT, Joo NS, et al. Esophagogastroduodenoscopy: insertion technique and training. Korean J Fam Pract 2013;3:272-98.
2. Chae DR, Kim HD, Lee JH, Kim SP, Jeon WJ, Kim SH, et al. A study of clinically relevant initial loading dose of propofol during upper gastrointestinal endoscopy using sedation with propofol. Korean J Med 2005;68:261-7.
3. Cohen LB, Wecsler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol 2006;101:967-74.
4. Park HJ, Son BK, Koo HS, Kim BW. Preparation, evaluation, and recovery before and after conscious sedative endoscopy. Korean J Gastroenterol 2017;69:59-63.
5. Ryu HG. Requirements and circumstances for safe sedation. J Korean Med Assoc 2013;56:299-302.
6. Yamamoto H, Gotoda T, Nakamura T, Yamamoto T, Kikuchi H, Kitamura M, et al. Clinical impact of gastroenterologist-administered propofol during esophagogastroduodenoscopy: a randomized comparison at a single medical clinic. Gastric Cancer 2015;18:326-31.
7. Kim KO. Assessement of patient’s status during sedation endoscopy. Korean J Gastrointest Endosc 2011;40:106-10.
8. Shin JY, Lee SH, Shin SM, Kim MH, Park SG, Park BJ. Prescribing patterns of the four most commonly used sedatives in endoscopic examination in Korea: propofol, midazolam, diazepam, and lorazepam. Regul Toxicol Pharmacol 2015;71:565-70.
9. Allampati S, Wen S, Liu P, Kupec JT. Recovery of cognitive function after sedation with propofol for outpatient gastrointestinal endoscopy. Saudi J Gastroenterol 2019;25:188-93.
10. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004-17.
11. Cohen LB, Delegee MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007;133:675-701.
12. Kim-JH, Kim DH, Kim JH. Low-dose midazolam and propofol use for conscious sedation during diagnostic endoscopy. Kaohsiung J Med Sci 2019;35:160-7.
13. Childers RE, Williams JL, Sonnenberg A. Practice patterns of sedation for colonoscopy. Gastrointest Endosc 2015;82:503-11.
14. Freoehlich F, Harris JK, Wietlisbach V, Burnand B, Vader JP, Convers JJ. Current sedation and monitoring practice for colonoscopy: an International Observational Study (EPAGE). Endoscopy 2006;38:461-9.
15. Pitetti R, Davis PJ, Redlinger R, White J, Wiener E, Calhoun KH. Effect on hospital-wide sedation practices after implementation of the 2001 JCAHO procedural sedation and analgesia guidelines. Arch Pediatr Adolesc Med 2006;160:211-6.
16. Triantafillidis JK, Merikas E, Nikolakis D, Papalois AE. Sedation in gastrointestinal endoscopy: current issues. World J Gastroenterol 2013;19:463-81.
17. Koo JS, Choi JH. Conscious sedation during gastrointestinal endoscopy: midazolam vs propofol. Korean J Gastrointest Endosc 2011;42:67-73.
18. Cohen LB, Hightower CD, Wood DA, Miller KM, Aisenberg J. Moderate level sedation during endoscopy: a prospective study using low-dose propofol, meperidine/fentanyl, and midazolam. Gastrointest Endosc 2004;59:795-803.
19. Lugay M, Otto G, Kong M, Mason DJ, Wilets I. Recovery time and safe discharge of endoscopy patients after conscious sedation. Gastroenterol Nurs 1996;19:194-200.
20. Choi SH, ChoiKwon SM. A study on recovery time and factors related to recovery after sedative gastroscopy. J Korean Biol Nurs Sci 2006;8:49-59.
21. Eschenfeldt PC, Kartoun U, Heberle CR, Kong CY, Nishioka NS, Ng K, et al. Analysis of factors associated with extended recovery time after colonoscopy. PLoS One 2018;13:e0199246.
22. Newman DH, Azer MM, Pitetti RD, Singh S. When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations. Ann Emerg Med 2003;42:627-35.